FIGO 2018宫颈癌分期分析

IF 16.4 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Leila Cristina Soares, José Carlos Damian Junior, Ricardo José de Souza, Marco Aurélio Pinho de Oliveira
{"title":"FIGO 2018宫颈癌分期分析","authors":"Leila Cristina Soares, José Carlos Damian Junior, Ricardo José de Souza, Marco Aurélio Pinho de Oliveira","doi":"10.4274/jtgga.galenos.2022.2022-1-10","DOIUrl":null,"url":null,"abstract":"Cancer staging is a process that changes with technological development leading to improvements in diagnosis, prognosis, and treatment. Therefore, the International Federation of Gynecology and Obstetrics (FIGO) updated the classification of cervical cancer staging in 2018. The main changes in the FIGO 2018 system occurred in stages IA, IB, and IIIC, as well as the inclusion of any imaging modality or pathological findings to allocate the stage (1). However, some conditions still need adjustments to differentiate each stage of the system. Only the depth of invasion is now considered as the cut-off for stage IA, assigning stage IA as stroma invasion less than 5.0 mm, and further subdivided into stage IA1 and IA2 at a cutoff of 3.0 mm (1). The change at this stage was about the lateral extent of the lesion, which is no longer considered. After removing the lateral extent criterion, there is a concern with different cases being analyzed in the same way. It is also unclear whether clinically visible cases with stromal infiltration up to 3 mm would be IA1 or IB stage. Tumor size has been recognized as a prognostic factor in stage IB for a long time, with larger tumor sizes displaying higher rates of nodal involvement, and decreased survival rates (2). At this stage, FIGO 2018 has included three substages, rather than two. In terms of stage IIIB, Katanyoo (3) demonstrated that patients with a lower third vaginal invasion associated with parametrial involvement have poorer survival outcomes than patients at the same stage without a lower third of vaginal invasion. More studies are needed to verify these findings. However, if the finding of vaginal invasion in IIIB has worse prognosis, our suggestion is that stage IIIB should be subdivided into stage IIIB1, with involvement of only the parametrium, and IIIB2, with involvement of the lower third of the vagina and parametrium. In FIGO 2018, any patient with positive lymph nodes automatically gets upstaged to stage IIIC (1). Ayhan et al. (2) suggested an increase in the number of sub-stages. This classification might be more prognostic than the current 2018 FIGO staging system, as more patients would be allocated to each sub-stage (2). We suggest that lymph node involvement accompany each stage without modifying the original stage instead of grouping them in stage IIIC. Radiotherapy may be of limited value for patients with cervical adenocarcinoma and may not represent the best treatment, being an important prognostic factor for local failure (4). Different prognoses and treatment needs within the same stage would require some differentiation, as in endometrial cancer, where the serous papillary type is considered highgrade endometrial carcinoma (FIGO grade 3) (5). An optimal staging system should assign cases to prognostic categories, define the anatomical extent of disease, refer patients for individualized treatments, and compare patients and their outcomes between centers (1,2). These observations on staging, considering new discriminations, could contribute to better understanding and planning through better prognostic accuracy for cervical cancer, reflecting differences in survival and guiding treatment.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2022-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/00/JTGGA-23-325.PMC9743344.pdf","citationCount":"1","resultStr":"{\"title\":\"Critical analysis of the FIGO 2018 cervical cancer staging\",\"authors\":\"Leila Cristina Soares, José Carlos Damian Junior, Ricardo José de Souza, Marco Aurélio Pinho de Oliveira\",\"doi\":\"10.4274/jtgga.galenos.2022.2022-1-10\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cancer staging is a process that changes with technological development leading to improvements in diagnosis, prognosis, and treatment. Therefore, the International Federation of Gynecology and Obstetrics (FIGO) updated the classification of cervical cancer staging in 2018. The main changes in the FIGO 2018 system occurred in stages IA, IB, and IIIC, as well as the inclusion of any imaging modality or pathological findings to allocate the stage (1). However, some conditions still need adjustments to differentiate each stage of the system. Only the depth of invasion is now considered as the cut-off for stage IA, assigning stage IA as stroma invasion less than 5.0 mm, and further subdivided into stage IA1 and IA2 at a cutoff of 3.0 mm (1). The change at this stage was about the lateral extent of the lesion, which is no longer considered. After removing the lateral extent criterion, there is a concern with different cases being analyzed in the same way. It is also unclear whether clinically visible cases with stromal infiltration up to 3 mm would be IA1 or IB stage. Tumor size has been recognized as a prognostic factor in stage IB for a long time, with larger tumor sizes displaying higher rates of nodal involvement, and decreased survival rates (2). At this stage, FIGO 2018 has included three substages, rather than two. In terms of stage IIIB, Katanyoo (3) demonstrated that patients with a lower third vaginal invasion associated with parametrial involvement have poorer survival outcomes than patients at the same stage without a lower third of vaginal invasion. More studies are needed to verify these findings. However, if the finding of vaginal invasion in IIIB has worse prognosis, our suggestion is that stage IIIB should be subdivided into stage IIIB1, with involvement of only the parametrium, and IIIB2, with involvement of the lower third of the vagina and parametrium. In FIGO 2018, any patient with positive lymph nodes automatically gets upstaged to stage IIIC (1). Ayhan et al. (2) suggested an increase in the number of sub-stages. This classification might be more prognostic than the current 2018 FIGO staging system, as more patients would be allocated to each sub-stage (2). We suggest that lymph node involvement accompany each stage without modifying the original stage instead of grouping them in stage IIIC. Radiotherapy may be of limited value for patients with cervical adenocarcinoma and may not represent the best treatment, being an important prognostic factor for local failure (4). Different prognoses and treatment needs within the same stage would require some differentiation, as in endometrial cancer, where the serous papillary type is considered highgrade endometrial carcinoma (FIGO grade 3) (5). An optimal staging system should assign cases to prognostic categories, define the anatomical extent of disease, refer patients for individualized treatments, and compare patients and their outcomes between centers (1,2). These observations on staging, considering new discriminations, could contribute to better understanding and planning through better prognostic accuracy for cervical cancer, reflecting differences in survival and guiding treatment.\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2022-12-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/00/JTGGA-23-325.PMC9743344.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/jtgga.galenos.2022.2022-1-10\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/jtgga.galenos.2022.2022-1-10","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 1

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Critical analysis of the FIGO 2018 cervical cancer staging
Cancer staging is a process that changes with technological development leading to improvements in diagnosis, prognosis, and treatment. Therefore, the International Federation of Gynecology and Obstetrics (FIGO) updated the classification of cervical cancer staging in 2018. The main changes in the FIGO 2018 system occurred in stages IA, IB, and IIIC, as well as the inclusion of any imaging modality or pathological findings to allocate the stage (1). However, some conditions still need adjustments to differentiate each stage of the system. Only the depth of invasion is now considered as the cut-off for stage IA, assigning stage IA as stroma invasion less than 5.0 mm, and further subdivided into stage IA1 and IA2 at a cutoff of 3.0 mm (1). The change at this stage was about the lateral extent of the lesion, which is no longer considered. After removing the lateral extent criterion, there is a concern with different cases being analyzed in the same way. It is also unclear whether clinically visible cases with stromal infiltration up to 3 mm would be IA1 or IB stage. Tumor size has been recognized as a prognostic factor in stage IB for a long time, with larger tumor sizes displaying higher rates of nodal involvement, and decreased survival rates (2). At this stage, FIGO 2018 has included three substages, rather than two. In terms of stage IIIB, Katanyoo (3) demonstrated that patients with a lower third vaginal invasion associated with parametrial involvement have poorer survival outcomes than patients at the same stage without a lower third of vaginal invasion. More studies are needed to verify these findings. However, if the finding of vaginal invasion in IIIB has worse prognosis, our suggestion is that stage IIIB should be subdivided into stage IIIB1, with involvement of only the parametrium, and IIIB2, with involvement of the lower third of the vagina and parametrium. In FIGO 2018, any patient with positive lymph nodes automatically gets upstaged to stage IIIC (1). Ayhan et al. (2) suggested an increase in the number of sub-stages. This classification might be more prognostic than the current 2018 FIGO staging system, as more patients would be allocated to each sub-stage (2). We suggest that lymph node involvement accompany each stage without modifying the original stage instead of grouping them in stage IIIC. Radiotherapy may be of limited value for patients with cervical adenocarcinoma and may not represent the best treatment, being an important prognostic factor for local failure (4). Different prognoses and treatment needs within the same stage would require some differentiation, as in endometrial cancer, where the serous papillary type is considered highgrade endometrial carcinoma (FIGO grade 3) (5). An optimal staging system should assign cases to prognostic categories, define the anatomical extent of disease, refer patients for individualized treatments, and compare patients and their outcomes between centers (1,2). These observations on staging, considering new discriminations, could contribute to better understanding and planning through better prognostic accuracy for cervical cancer, reflecting differences in survival and guiding treatment.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Accounts of Chemical Research
Accounts of Chemical Research 化学-化学综合
CiteScore
31.40
自引率
1.10%
发文量
312
审稿时长
2 months
期刊介绍: Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信